Silence Therapeutics (SLN) Total Non-Current Liabilities (2019 - 2024)
Historic Total Non-Current Liabilities for Silence Therapeutics (SLN) over the last 6 years, with Q3 2024 value amounting to -$75.3 million.
- Silence Therapeutics' Total Non-Current Liabilities rose 80.05% to -$75.3 million in Q3 2024 from the same period last year, while for Sep 2024 it was -$75.3 million, marking a year-over-year increase of 80.05%. This contributed to the annual value of -$73.2 million for FY2023, which is 19320.61% down from last year.
- Per Silence Therapeutics' latest filing, its Total Non-Current Liabilities stood at -$75.3 million for Q3 2024, which was up 80.05% from -$73.4 million recorded in Q2 2024.
- Silence Therapeutics' Total Non-Current Liabilities' 5-year high stood at $97.7 million during Q4 2021, with a 5-year trough of -$90.0 million in Q1 2022.
- In the last 5 years, Silence Therapeutics' Total Non-Current Liabilities had a median value of -$75.3 million in 2022 and averaged -$48.5 million.
- Per our database at Business Quant, Silence Therapeutics' Total Non-Current Liabilities soared by 23982.31% in 2020 and then tumbled by 19834.59% in 2023.
- Silence Therapeutics' Total Non-Current Liabilities (Quarter) stood at $67.8 million in 2020, then soared by 44.17% to $97.7 million in 2021, then decreased by 23.81% to $74.5 million in 2022, then plummeted by 198.35% to -$73.2 million in 2023, then decreased by 2.83% to -$75.3 million in 2024.
- Its Total Non-Current Liabilities was -$75.3 million in Q3 2024, compared to -$73.4 million in Q2 2024 and -$71.4 million in Q1 2024.